Anti mouse ctla 4 9d9

Manufactured by BioXCell

Sourced in United States

Anti-mouse CTLA-4 (9D9) is a laboratory product. It is a monoclonal antibody that binds to the mouse cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

Automatically generated - may contain errors

Lab products found in correlation

Nutlin 3a, by Bio-Techne (1 mentions) Rg7112, by MedChemExpress (1 mentions) Mi 773, by MedChemExpress (1 mentions) Rmp1 14, by BioXCell (1 mentions) Pembrolizumab, by Merck Group (1 mentions) Bevacizumab, by Genentech (1 mentions) Anti mouse pd1 rmp1 14, by BioXCell (1 mentions)

Close spelling variants of this product

Anti-mouse CTLA-4 (5 citations) Anti–CTLA-4 (9D9 (4 citations) CTLA-4, (2 citations)

2 protocols using anti mouse ctla 4 9d9

Novel MDM2 Antagonists and Immunotherapies for Cancer

Check if the same lab product or an alternative is used in the 5 most similar protocols

The MDM2 antagonists Nutlin‐3a (Tocris; #3984), SAR405838 (MedchemExpress; MI‐773, #HY‐17493) and RG7112 (MedchemExpress; #HY‐10959), bevacizumab (Genentech; CAS, 216974‐75‐3), pembrolizumab (Merck, Kenilworth, NJ, USA), anti‐mouse PD‐L1 (10F9G2, BioXcell, USA), anti‐mouse CTLA‐4 (9D9, BioXcell, USA), and anti‐mouse PD‐1 (RMP1‐14, BioXcell, USA) were purchased from commercial suppliers as indicated and used with no further purification. AD‐04 and ent‐AD‐04 were synthesized according to O'Dowd et al.
²³ (link) ADC‐159 was synthesized according to the procedure outlined in the Supporting Information.

Jurisic A., Sung P., Wappett M., Daubriac J., Lobb I.T., Kung W., Crawford N., Page N., Cassidy E., Feutren‐Burton S., Rountree J.S., Helm M.D., O'Dowd C.R., Kennedy R.D., Gavory G., Cranston A.N., Longley D.B., Jacq X, & Harrison T. (2024). USP7 inhibitors suppress tumour neoangiogenesis and promote synergy with immune checkpoint inhibitors by downregulating fibroblast VEGF. Clinical and Translational Medicine, 14(4), e1648.

+ Open protocol

+ Expand

In Vivo CD8+ T Cell Depletion and ICI

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies for in vivo depletion of CD8 + T cells -anti-mouse CD8a (53-6.7) -and in vivo ICI treatment -anti-mouse PD-1 (RMP1-14) and anti-mouse CTLA-4 (9D9) -were purchased from Bio X Cell (USA). For T cell depletion, anti-CD8 depleting antibody was administered i.p. at 10 mg/kg on days -2, 0, and every 7 days ongoing, relative to the time of tumor cell injection. For efficacy studies, treatments were administered i.p. at 10 mg/kg once the tumors reached an average size of 80-100 mm 3 and a total of four doses was given every second to third day, unless specified otherwise. For 7-day treatments, tumors were allowed to grow until they reached a size of approximately 500 mm 3 and treated i.p. at 10 mg/kg with a total of two doses.

Stanczak M.A., Mantuano N.R., Kirchhammer N., Sanin D.E., Wang J., Trefny M.P., Monaco G., Gray M.A., Petrone A., Kashyap A.S., Glatz K., Kasenda B., Normington K., Broderick J., Li P., Pearce O.M., Pearce E.L., Bertozzi C.R., Zippelius A., & Läubli H. (2021). Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!